NCT02508935View on ClinicalTrials.gov

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

PHASE4TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

April 26, 2017

Study Completion Date

April 26, 2017

Conditions
Acute Pain
Interventions
DRUG

XARTEMIS XR

XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets

Trial Locations (2)

15213

University of Pittsburgh Medical Center, University of Pittsburgh Physicians, Pittsburgh

27710

Duke University Health Systems, Durham

Sponsors

Lead Sponsor

Mallinckrodt
All Listed Sponsors
lead

Mallinckrodt

INDUSTRY

NCT02508935 - Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain | Biotech Hunter | Biotech Hunter